BRAF and colorectal carcinoma: Thus, OBP-702 treatment may contribute to the induction of apoptosis in BRAF-mutant CRC cells by suppressing the AKT-mTOR and EGFR-MEK-ERK signaling pathways and activating the p53 signaling pathway.